User login
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
